SCHEMBL29327032

SCHEMBL29327032

Clc1cccc(C2=CC=CCC2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.46
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
ALOX5 P09917 1/20 0.38
IDO1 P14902 1/20 0.38
TAAR1 Q96RJ0 2/20 0.37
ESR2 Q92731 1/20 0.35
NOTUM Q6P988 1/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
RAB9A P51151 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SCN2A Q99250 1/20 0.35
HTR7 P34969 2/20 0.35
PARP10 Q53GL7 1/20 0.35
PARP11 Q9NR21 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8181096 0.79 SIGMAR1 (0.38) HTR2CALOX5NPC1TSHRRAB9A
SCHEMBL9377713 0.79 HTR2C (0.62) HTR2CCHRNB4CHRNA3ALOX5IDO1
SCHEMBL13139758 0.79 CHRNB4 (0.40) CHRNB4CHRNA3IDO1TAAR1ESR2
SCHEMBL18562454 0.79 CHRNB4 (0.40) CHRNB4CHRNA3IDO1NPC1TP53
SCHEMBL13782314 0.79 CHRNB4 (0.40) CHRNB4CHRNA3
SCHEMBL19231991 0.79 MAOA (0.44)
SCHEMBL787585 0.78 ALDH1A1 (0.36) HTR2CCHRNB4CHRNA3SCN2A
SCHEMBL28274500 0.76 AHR (0.46) NOTUMNPC1TP53RAB9A
SCHEMBL29355374 0.76 NISCH (0.40)
SCHEMBL25907172 0.76 CYP2A6 (0.38) TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF ASIA VISION LIMITED (CN) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF BCL2, BCL2L2, BCL2L1 HTR2C 3380/4885CHRNB4 4666/4885CHRNA3 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.